CD73 Blockade Aggravate Dextran-Sodium-Sulfate-Induced Colitis via Down Regulating Inosine

Area of Science:

• Immunology
• Gastroenterology
• Biochemistry

Background:

• CD73 is an enzyme crucial for purinergic signaling, regulating adenosine and inosine levels.
• These metabolites influence immune and inflammatory responses.
• The role of CD73 in inflammatory bowel disease (IBD) pathogenesis requires further investigation.

Purpose of the Study:

• To investigate the function of CD73 in the pathogenesis of inflammatory bowel disease (IBD).
• To explore the underlying mechanisms of CD73's action in IBD.
• To evaluate inosine as a potential therapeutic agent for colitis.

Main Methods:

• Dextran-Sodium-Sulfate (DSS)-induced colitis mouse models were used.
• CD73 was blocked using Adenosine 5'- (α, β-methylene) diphosphate (APCP); inosine was supplemented.
• Histological analysis (H&E, PAS, Alcian blue), ELISA for IL-6, and LC-MS for inosine levels were performed.

Main Results:

• Blocking CD73 aggravated DSS-induced colitis, increasing weight loss, colon damage, and IL-6 production.
• CD73 blockade impaired intestinal barrier function by reducing tight junction proteins and increased oxidative stress.
• Inosine treatment significantly ameliorated colitis symptoms and counteracted the effects of CD73 blockade.

Conclusions:

• CD73 exhibits a protective effect in DSS-induced colitis.
• Inosine supplementation demonstrates therapeutic potential for colitis treatment.
• Modulating CD73 and inosine levels offers a promising strategy for managing IBD.